Comparative efficacy and safety of anti-infective drugs for patients with mild to severe COVID-19: A systematic review and network meta-analysis of randomized controlled trials
Ethiop. Med. j
; 61(2): 171-188, 2023. tables, figures
Article
в En
| AIM
| ID: biblio-1426999
Ответственная библиотека:
CG1.1
ABSTRACT
Different anti-infecthe drugs have been proposedfor the treatment ofpatients with COVID-19. We carried out a network meta-analysis to assess their relath'e efficacy and safety. Methods:
We searched relevant databases for all randomized controlled trials that reported the efficacy and or safety ofany anti-infective drugs published up to April 30, 2022 for different outcomes. We did both painvise and network meta-analysis with 95% confidence intervals using afixed-effect model. We assessed studies for quality of evidence using an extension of the standard Grading ofRecommendations, Assessment, Development and Evaluation approach considering PConclusion:
This Network Meta-analysis suggests that Baricitinib plus Remdesivir is more effective than the other anti-infective drugs in treating patients with COVID-19 in terms of clinical recovery at 14 days, mortality and adverse events outcomes.Key words
Полный текст
- https://indexmedicus.afro.who.int/iah/fulltext/Comparative efficacy and safety of anti infective drugs for patients with mild to severe COVID 19 A systematic review and network meta analysis of randomized controlled trials.pdf
- https://emjema.org/index.php/EMJ/article/view/2211/897
- https://fi-admin.bvsalud.org/document/view/cm8uy
Полный текст:
1
База данных:
AIM
Основная тема:
Randomized Controlled Trial
/
COVID-19
/
COVID-19 Drug Treatment
Тип исследования:
Clinical_trials
/
Systematic_reviews
Пределы темы:
Humans
Язык:
En
Журнал:
Ethiop. Med. j
Год:
2023
Тип:
Article